Corporate Communications | Sutro Biopharma, Inc.

SutroVax Announces Closing of $64M via Series B Financing

SutroVax Announces Closing of $64M via Series B Financing Foster City, CA, March 21, 2017 – SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious...

Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma

Press Releases

Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma SOUTH SAN FRANCISCO, December 6, 2016 – Sutro Biopharma Inc. today announced that it has launched IND-enabling...

BioTech Nation Radio with CEO Bill Newell

Events

BioTech Nation Radio with CEO Bill Newell NPR and BioTech Nation interview Sutro’s CEO William Newell to learn more about the next generation of cancer therapeutics. Click here to listen to the conversation as Bill describes Sutro’s discovery and...

Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma

Press Releases

Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma SAN FRANCISCO, Sept. 19, 2016 — Sutro Biopharma Inc. today announced that it has presented findings from two studies of...

Sutro Marks Important Progress — Receives Two Milestone Payments from Celgene

Press Releases

Sutro Marks Important Progress — Receives Two Milestone Payments from Celgene SAN FRANCISCO, Sept. 7, 2016 – Sutro Biopharma Inc. today announced that it has received two milestone payments from drug discovery and development partner Celgene Corporation...

« Older Entries

Next Entries »